Drugs from China are reshaping biotech. Track the licensing deals here.
Written by
BioPharma Dive
Published
0
comments
0
min
Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing hitting a record pace in 2025. Follow this year’s dealmaking with this database.